Antiarrhythmic properties of ivabradine in an experimental model of Short-QT- Syndrome.

about

Antiarrhythmic properties of ivabradine in an experimental model of Short-QT- Syndrome.

Item

http://www.wikidata.org/entity/Q38757022

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Antiarrhythmic properties of ivabradine in an experimental model of Short-QT- Syndrome.

@en

type

Item

label

Antiarrhythmic properties of ivabradine in an experimental model of Short-QT- Syndrome.

@en

prefLabel

Antiarrhythmic properties of ivabradine in an experimental model of Short-QT- Syndrome.

@en

P1476

Antiarrhythmic properties of ivabradine in an experimental model of Short-QT- Syndrome.

@en

P2093

Christian Ellermann

http://www.w3.org/2001/XMLSchema#string

Dirk G Dechering

http://www.w3.org/2001/XMLSchema#string

Jan Weller

http://www.w3.org/2001/XMLSchema#string

Philipp S Lange

http://www.w3.org/2001/XMLSchema#string

Sven Kaese

http://www.w3.org/2001/XMLSchema#string

P2860

A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene

Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.

Sudden death associated with short-QT syndrome linked to mutations in HERG.

hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.

Ivabradine reduced ventricular rate in patients with non-paroxysmal atrial fibrillation.

Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4.

Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation.

Ranolazine and Vernakalant Prevent Ventricular Arrhythmias in an Experimental Whole-Heart Model of Short QT Syndrome.

Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects.

If inhibition in the atrioventricular node by ivabradine causes rate-dependent slowing of conduction and reduces ventricular rate during atrial fibrillation.

P304

941-945

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1440-1681.12790

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lars Eckardt

Gerrit Frommeyer

Simon Kochhäuser

P577

2017-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28556923

http://www.w3.org/2001/XMLSchema#string